This is research, not a buy or sell recommendation. Robo-advice in Taiwan requires an FSC licence; FEAF analyses, explains and monitors, and the investor makes the decision. Judgement thresholds are working rules pending review by the team's finance members.
Plain-language summary of valuation, growth, profitability, balance sheet, and recent MOPS filings.
Your risk profile
Conclusion
Mixed picture: 2 strengths against 4 watch-outs. Weigh them against your own goals.
Points to watch for a moderate profile: see the items marked above.
No model narrative: the model call failed. The structured analysis above is complete on its own.
Strengths
+
Liabilities are only 35.5% of total assets (Q3 2026): a light debt load. source (Financials) →
+
Free cash flow was positive in 2025: 312 NT$ million. source (Financials) →
Watch-outs
!
The current price implies 4.8% perpetual growth, above the 3.5% ceiling: the price already assumes high expectations. source (Valuation) →
!
P/E 103.97 is well above the Chemicals median of 18.46 (26 listed peers): priced richer than peers. source (Key Stats) →
!
Revenue fell -7.3% in 2025; latest quarter Q3 2026: 27.4% year on year. source (Financials) →
!
Return on equity 2.1% with a 2.3% net margin: weak profitability. source (Key Stats) →
What to check before deciding
?Can the company sustain growth above the perpetual-growth ceiling for years?
?Why is it priced above its peers, and is that premium justified?
?Is the revenue decline temporary or structural?
?What would lift profitability, and how soon?